Advertisement

Revista de Oncología

, Volume 2, Issue 5, pp 231–237 | Cite as

Neoadjuvant and adjuvant chemotherapy in bladder cancer

  • Miguel A. Climent Durán
  • Vicente Guillem Porta
Revisiones
  • 25 Downloads

Abstract

State of the art treatment for invasive bladder cancer is cystectomy. Intensive clinical investigation has been performed in the last years about the role of neoadjuvant and adjuvant chemotherapy. Although neoadjuvant treatment seems not to increase long-term survival, it seems to play a role in the possibility of bladder preservation strategies. Adjuvant chemotherapy, in high-risk patients, seems to improve disease-free survival and time to progression. Nevertheless, new prospective studies should be performed to clarify its role in improving survival.

Key words

Bladder cancer adjuvant chemotherapy neoadjuvant chemotherapy 

Quimioterapia neoadyuvante y adyuvante en el cáncer de vejiga

Resumen

Aunque el tratamiento estándar del carcinoma de vejiga infiltrante localizado es la cistectomía radical, durante la Última década se ha investigado intensamente el papel de la quimioterapia, administrada tanto de forma neoadyuvante como adyuvante. Aunque la quimioterapia neoadyuvante no parece haber obtenido un aumento de las tasas de supervivencia a largo plazo, puede permitir tratamientos locales menos agresivos con preservación funcional del órgano. La quimioterapia adyuvante, administrada en los pacientes que tras la cistectomía presentan factores de alto riesgo de recaída, parece que aumenta el intervalo libre de recaída y el tiempo a la progresión, aunque su contribución a una mejoría en la supervivencia debe aclararse llevando a cabo estudios prospectivos randomizados adecuados.

Palabras clave

cáncer de vejiga quimioterapia adyuvante quimioterapia neoadyuvante 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sternberg CN, Sher HI. Current status of chemotherapy of urothelial tract. Oncology 1987; 5: 41–41.Google Scholar
  2. 2.
    Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblatine, and doxorrubicinin patients with metastasic urothelial carcinoma: a cooperative group study. J Clin Oncol1992; 10(7): 1.066–1.073.Google Scholar
  3. 3.
    Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorrubicin, and cisplatin) for transitional cell carcinoma of the urothelium. JUrol 1985; 133: 403–407.Google Scholar
  4. 4.
    Harker WG, Meyers FJ, Freiha FS, et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen in metastatic transitional cell carcinoma of the urinary tract. A Nothern California Oncology Group Study. J Clin Oncol 1985; 3: 1.463–1.470.Google Scholar
  5. 5.
    Stoter G, Splinter TAW, Child JA, et al for the European Organization for Research on Treatment of Cancer Geniturinary Group. Chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. JUrol 1987; 137: 663–667.Google Scholar
  6. 6.
    Logothetis CJ, Samuels ML, Ogden S, et al. Cyclophosphamide, doxorrubicin and cisplatin chemotherapy for patients with locally advanced urothepial tumors with or without nodal metastases. JUrol 1985; 134: 460–464.Google Scholar
  7. 7.
    Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastasic urothelial tumors. J Clin Oncol 1990; 8(6): 1.050–1.055.Google Scholar
  8. 8.
    Martínez Piñeiro JA, Martínez Piñeiro L. The role of neoadjuvant chemotherapy for invasive bladder cancer. Br J Urol 1998; 82: 33–42.CrossRefPubMedGoogle Scholar
  9. 9.
    Coppin CML, Gospodarowicz MK, James K, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation J Clin Oncol 1996; 14: 2.901–2.907.Google Scholar
  10. 10.
    Wallace DMA, Raghavan D, Kelly KA, et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 1991; 67: 608–615.CrossRefPubMedGoogle Scholar
  11. 11.
    Martínez-Piñeiro JA, González Martín M, Arocena F, et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 1995; 153: 964–973.CrossRefPubMedGoogle Scholar
  12. 12.
    Shearer RJ, Chilvers CED, Bloom HJG, Bliss JM, Horwich A, Babiker A, for the Cooperative Urological Cancer Group. Adjuvant chemotherapy in T3 carcinoma of the bladder. A retrospective trial: preliminary report. Br J Urol 1988; 62: 558–564.CrossRefPubMedGoogle Scholar
  13. 13.
    MÄlmstrom PU, Rintala E, Wahlquvist R, et al. Five-year follow up of a retrospective trial of radical cystectomy and neoadjuvant chemohterapy: nordic cystectomy trial L J Urol 1996; 155: 1.903–1.906.CrossRefGoogle Scholar
  14. 14.
    Abol-Enein H, El-Mekresh M, El-Baz M, Ghoneim MA. Neo-adjuvant chemotherapy in the treatment of invasive transitional bladder cancer. A controlled, prospective randomized study. Br J Urol 1997; 79 (4 Supl): 174.Google Scholar
  15. 15.
    Shipley WU, Winter KA, Kaufman WR, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998; 16: 3.576–6.583.Google Scholar
  16. 16.
    International collaboration of trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlles trial. Lancet 1999; 354: 533–540.CrossRefGoogle Scholar
  17. 17.
    Splinter TAW, Sher HI, and the EORTC-GU Group. The prognostic value of the pT category after combination chemotherapy for patients with invasive bladder cancer who underwent cystectomy. In: Splinter TAW, Sher HI, eds. Neoadjuvant chemotherapy in invasive bladder cancer. New York: Wiley-Liss, 1990; 219–224.Google Scholar
  18. 18.
    Angulo JC, Sánchez Chapado M, López JI, Flores N. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: a multivariate analysis on prognostic factors. J Urol 1987; 155: 1.897–1.902.CrossRefGoogle Scholar
  19. 19.
    Sher HI, Herr H, Sternberg C, et al. Neoadjuvant chemotherapy for invasive bladder cancer. Experience with the MVAC regimen. Br J Urol 1989; 64: 250–256.CrossRefGoogle Scholar
  20. 20.
    Schulz PK, Herr HW, Zhang ZF, et al. Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol 1994; 12: 1.394–1.401.Google Scholar
  21. 21.
    Sternberg CN, Arena MG, Calabresi F, et al. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorrubicin and cisplatin) for infiltrating transitional cell carcinoma of the bladder. Cancer 1993; 72: 1.975–1.982.CrossRefGoogle Scholar
  22. 22.
    Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 1998; 16: 1.298–1.301.Google Scholar
  23. 23.
    Sternberg CN. Organ conservation in T2-T3 bladder cancer: the role of transurethral resection, partial cistectomy, and primary adjuvant chemotherapy. World J Urol 1991; 10: 2–7.Google Scholar
  24. 24.
    Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, Efird JT. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 1993; 329: 1.377–1.382.CrossRefGoogle Scholar
  25. 25.
    Hall RR, Roberts JT. Neoadjuvant chemotherapy, a method to conserve the bladder? [resumen]. Eur J Cancer 1991(2Supl): 144.Google Scholar
  26. 26.
    Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L. Aggresive TURB combined with systemic chemotherapy for locally invasive TCC of the urinary bladder. A second report (resumen). Eur J Cancer 1991 (2 Supl): 605.Google Scholar
  27. 27.
    Simon SD, Srougi M. Primary methotrexate, vinblastine, doxorrubicin and cisplatin chemotherapy and bladder preservation in locally invasive bladder cancer: a 5 year follow-up. J Urol 1994; 151: 593–597.PubMedGoogle Scholar
  28. 28.
    Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Calabuig C. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: long term follow up of a prospective study. J Urol 1998; 159: 95–99.CrossRefPubMedGoogle Scholar
  29. 29.
    Herr HE, Scher HI. Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. J Clin Oncol 1994; 12: 975–980.PubMedGoogle Scholar
  30. 30.
    Herr H, Whitmore W, Morse M, Sogani PC, Russo P, Fair W. Neoadjuvant chemotherapy in invasive bladder cancer: the evolving role of surgery. J Urol 1990; 144: 1.083–1.088.Google Scholar
  31. 31.
    Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group. Phase II Trial 8802. J Clin Oncol 1996; 14: 119–126.PubMedGoogle Scholar
  32. 32.
    Rifkin MN, Oblon D, Parsons J, et al. Bladder-sparing treatment of muscle invasive bladder cancer with systemic chemotherapy followed by radiation therapy and adjuvant cisplatin: a 3-year follow-up (resumen). Proc Am Soc Clin Oncol 1992; 11: 198.Google Scholar
  33. 33.
    Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993; 11: 2.150–2.157.Google Scholar
  34. 34.
    Skinner DG, Daniels JR, Russel CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991; 145: 459–467.PubMedGoogle Scholar
  35. 35.
    Clyne CA, Jenkins JD, Smart CJ, et al. A trial of adjuvant chemotherapy for stage T3 bladder tumors. J Urol 1983; 129: 736–737.Google Scholar
  36. 36.
    Merrin C, Beckley S. Adjuvant chemotherapy for bladder cancer with doxorrubicin hydrochloride and cyclo-phosphamide: preliminary report. J Urol 1978; 119: 62–63.PubMedGoogle Scholar
  37. 37.
    Logothetis CJ, Johnson DE, Chong C, et al. Adjuvant cyclophosphamide, doxorrubicin and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol 1988; 6: 1.590–1.596.Google Scholar
  38. 38.
    Fradet Y, Chin JZ, Carrier S, et al. Adjuvant MVAC chemotherapy after radical cystectomy for invasive bladder cancer (resumen). J Urol 1992; 147: 446A.Google Scholar
  39. 39.
    Kobayashi H, Obata K. Results of adjuvant chemotherapy for invasive urothelial cancer with lymph-node metastases. Cancer Chemother Pharmacol 1994; 35: 14–17.CrossRefGoogle Scholar
  40. 40.
    Studer UE, Bacchi M, Biedermann C, et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 1994; 152: 81–84.PubMedGoogle Scholar
  41. 41.
    Stöckle M, Meyenburg W, Wellek S, et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and N2) improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992; 148: 302–307.PubMedGoogle Scholar
  42. 42.
    Freiha F, Reese J, Torti F. A randomized trial of radical cystectomyuersus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996; 155: 495–500.CrossRefPubMedGoogle Scholar

Copyright information

© FESEO 2000

Authors and Affiliations

  • Miguel A. Climent Durán
    • 1
  • Vicente Guillem Porta
    • 1
  1. 1.Servicio de Oncología MédicaFundación Instituto Valenciano de OncologíaValencia

Personalised recommendations